| Market Cap | 9.75M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.84M | Forward P/E | -0.52 | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | 11.39M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | 0.36 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | - | Quick Ratio | 5.27 | Shares Outstanding | 3.65M | 52W Low Chg | 6.00% |
| Insider Own | 0.00% | ROA | -29.99% | Shares Float | 3.65M | Beta | 1.00 |
| Inst Own | 7.16% | ROE | -59.00% | Shares Shorted/Prior | 6.40K/8.08K | Price | 2.67 |
| Gross Margin | -21.36% | Profit Margin | -95.18% | Avg. Volume | 13,237 | Target Price | - |
| Oper. Margin | -380.22% | Earnings Date | Nov 7 | Volume | 8,455 | Change | 0.00% |
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
| HC Wainwright & Co. | Buy | Aug 15, 23 |
| HC Wainwright & Co. | Buy | May 15, 23 |
| HC Wainwright & Co. | Buy | Feb 7, 23 |
| HC Wainwright & Co. | Buy | Mar 30, 22 |